التفاصيل البيبلوغرافية
| العنوان: |
Type I interferon autoantibodies in hospitalized patients with Middle East respiratory syndrome and association with outcomes and treatment effect of interferon beta‐1b in MIRACLE clinical trial. |
| المؤلفون: |
Alotaibi, Faizah, Alharbi, Naif Khalaf, Rosen, Lindsey B., Asiri, Ayed Y., Assiri, Abdullah M., Balkhy, Hanan H., Al Jeraisy, Majed, Mandourah, Yasser, AlJohani, Sameera, Al Harbi, Shmeylan, Jokhdar, Hani A. Aziz, Deeb, Ahmad M., Memish, Ziad A., Jose, Jesna, Ghazal, Sameeh, Al Faraj, Sarah, Al Mekhlafi, Ghaleb A., Sherbeeni, Nisreen Murad, Elzein, Fatehi Elnour, AlMutairi, Badriah M. |
| المصدر: |
Influenza & Other Respiratory Viruses; Mar2023, Vol. 17 Issue 3, p1-8, 8p |
| مصطلحات موضوعية: |
MIDDLE East respiratory syndrome, INTERFERON beta 1b, AUTOANTIBODIES, HOSPITAL patients, TYPE I interferons, TREATMENT effectiveness, CLINICAL trials |
| مصطلحات جغرافية: |
MIDDLE East |
| مستخلص: |
Background: Type I interferons (IFNs) are essential antiviral cytokines induced upon respiratory exposure to coronaviruses. Defects in type I IFN signaling can result in severe disease upon exposure to respiratory viral infection and are associated with worse clinical outcomes. Neutralizing autoantibodies (auto‐Abs) to type I IFNs were reported as a risk factor for life‐threatening COVID‐19, but their presence has not been evaluated in patients with severe Middle East respiratory syndrome (MERS). Methods: We evaluated the prevalence of type I IFN auto‐Abs in a cohort of hospitalized patients with MERS who were enrolled in a placebo‐controlled clinical trial for treatment with IFN‐β1b and lopinavir‐ritonavir (MIRACLE trial). Samples were tested for type I IFN auto‐Abs using a multiplex particle‐based assay. Results: Among the 62 enrolled patients, 15 (24.2%) were positive for immunoglobulin G auto‐Abs for at least one subtype of type I IFNs. Auto‐Abs positive patients were not different from auto‐Abs negative patients in age, sex, or comorbidities. However, the majority (93.3%) of patients who were auto‐Abs positive were critically ill and admitted to the ICU at the time of enrollment compared to 66% in the auto‐Abs negative patients. The effect of treatment with IFN‐β1b and lopinavir‐ritonavir did not significantly differ between the two groups. Conclusion: This study demonstrates the presence of type I IFN auto‐Abs in hospitalized patients with MERS. [ABSTRACT FROM AUTHOR] |
|
Copyright of Influenza & Other Respiratory Viruses is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |
Full Text Finder